Post-Traumatic Headache Market Size, Share and Global Trend By Drug Type (Anti-inflammatory drugs, Acetylsalicylic acid, Acetaminophen, Migraine-specific abortant triptan, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Forecast, 2024-2032

Headache refers to persistent or long-lasting pain or aches in the head region of the body. Headache is a common result of traumatic brain injuries and can persist for a long period, even after mild head trauma. Increased attention to traumatic brain injuries has raised concern on post-traumatic headache, one of the most common consequences of traumatic brain injuries. The International Headache Society defines post-traumatic headache like the one which develops within seven days after traumatic brain injury. Post-traumatic headache is often associated with symptoms such as insomnia, poor concentration, dizziness, sensitivity to noise and bright lights, fatigue, and many others. Violence, motor vehicle accidents, sports injuries, and falls are common incidents that result in traumatic brain injuries. According to the American Migraine Foundation, almost 1.7 million traumatic brain injuries occur every year in the United States, having a significant impact on the lives of the patients.

The growth in global post-traumatic headache market is being driven by the increase in the incidences of traumatic brain injuries and advancements in the treatment of post-traumatic headache. The major mergers and acquisitions are also expected to drive the global post-traumatic headache market. For example, in 2017, AstraZeneca partnered with Grunenthal for the global rights of Zomig outside Japan, which will enable Grunenthal to have a major portion of the global post-traumatic headache market by 2025.

However, higher time duration and expenditure involved in a drug development process of post-traumatic headache is responsible for restraining the market growth in the forecast period. Also, stringent regulations imposed on approval of the drugs is another factor limiting the growth of post-traumatic headache market.

KEY PLAYERS COVERED

Some of the major companies that are present in the global post-traumatic headache market are Novartis AG, Johnson & Johnson Health Care Systems Inc., Impax Laboratories, LLC., AstraZeneca, Grunenthal, GlaxoSmithKline plc., Glenmark Pharmaceutical Inc., Pfizer Inc., Merck & Co., Inc., Aralez Pharmaceuticals Inc., and others.

SEGMENTATION

Among the route of administration, the oral route is the most preferred by the doctors and research scientist in R&D as it has more advantages over the intravenous route for post-traumatic headache patients. The oral route is painless, convenient, and cheap compared to injections. This segment is anticipated to hold a major proportion of the post-traumatic headache market during the forecast period.

KEY INSIGHTS

Prevalence of traumatic brain injuries and post-traumatic headache for key countries

Overview of patent analysis

Pipeline analysis

Key mergers and acquisitions

REGIONAL ANALYSIS

Geographically, the global post-traumatic headache market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to expand in the forecast period, owing to increased incidences of traumatic brain injuries, increased R&D for post-traumatic headache drugs, and advanced healthcare facilities. The global post-traumatic headache market is expected to expand in Europe and the Asia Pacific by 2025 as a result of growing awareness about post-traumatic care among the population.

Key Industry Developments    

• In April 2019, VA Greater Los Angeles Healthcare System, a part of U.S. Department of Veterans Affairs completed its clinical trial for Abobotulinumtoxina in treatment against post-traumatic headache.
• In September 2018, Teva Pharmaceutical Industries Ltd received U.S.FDA approval for its AJOVY, a humanized monoclonal antibody supplied in the form of injection for treatment of migraine in adults which can be a future treatment for post traumatic headache.